KRIYA.825

KRIYA.825 is an investigational adeno-associated virus (AAV) gene therapy being developed by Kriya Therapeutics for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The therapy is designed to deliver a genetic payload to retinal cells that enables the continuous, durable expression of a proprietary complement-inhibiting protein following a single administration. By modulating the complement system—a component of the innate immune response whose overactivation is a primary driver of retinal cell death in GA—KRIYA.825 aims to slow the progression of retinal lesions and preserve visual function. The program was significantly bolstered by Kriya's 2022 acquisition of Terraza Pharma, which specialized in locally expressed complement inhibitors. KRIYA.825 is intended for delivery via a one-time intravitreal injection, utilizing Kriya's proprietary engineering and manufacturing platforms to optimize protein expression and therapeutic reach.

Other names

CR2-CR1 fusion protein gene therapyCR-2-CR1 fusion protein gene therapyCR 2-CR1 fusion protein gene therapy